Literatur
Einführung
Weiterführende Bücher und Artikel sind hier am Ende des Textes zu-sammengefasst. Die aufgeführten 35 Bücher der letzten 10 Jahre ent-halten überblicke über die verschiedenartigsten Aspekte der Osteo-porose. Ausführliche Referenzlisten sind aus den Büchern zu entneh-men.
Zusätzlich zu den vielen anderen Büchern über die Osteoporose,die hier nicht aufgeführt werden konnten, sind in der internationalenLiteratur bereits eine "astronomische" Zahl von wissenschaftlichenArtikeln über alle Aspekte der Osteoporose erschienen. Diese sind imInternet verfügbar. Zum Beispiel haben allein die beiden Schlüssel-wörter "osteoporosis therapy" über 1000 Zitate im Zeitraum "Januarbis Juli 2003" ergeben. Es ist daher unmöglich, alle Osteoporose-rele-vanten Art ikel in diesem praktisch orientierten Buch zu berücksichti-gen. Es wurde allerdings der Versuch unternommen, alle für die Text-aussage des Buches und für die klinische Arbeit wichtigen Arbeiten zuzitieren und vor allem neueste Publikationen zu berücksichtigen. Die-se Artikel sind nach den jeweiligen Kapiteln des Buches gelistet.
Literatur zum Thema
. Osteoporose" - eine kaum
mehr überschaubare Flut!
220 Literatur----- ----
Bücher über Osteoporose
1. Avioli L (2000) The osteoporotic syndrome. Aeademic Press, San Diego2. Avioli L,Krane S (1997) Metabolie bone disease and clinically related disorders.
Aeademic Press, San Diego3. Barlow D,Francis R, Miles A (2001) The effeetive management of osteoporosis.
Aeseulapius Medical Press , London, San Francisco, Sydney4. Bart! R (2001) Osteoporose - Prävention, Diagnostik, Therapie. Thieme, Stutt-
gart, New York5. Bart! R (2002) Osteoporose: Erfolgreich vorbeugen und gezielt behandeln. Süd-
west Verlag, München6. Bart! R, Frisch B (1993) Biopsy ofbone in internal medicine - An at!as and sour-
eebook. Kluwer Aeademic Publ ishers, Dordrecht, Boston, London7. Bart! R, Frisch B (2002) Bisphosphonates for bones: Guidelines for treatment in
all medical disciplines. Blackwell, Berlin8. Bilezikian J, Raisz L, Rodan G (1996) Principles of bone biology. Aeademic
Press, San Diego9. Cummings S,Cosman F,[amal S (2002) Osteoporosis: An evidenee-based guide
to prevention and therapy. American College of Physicians, Philadelphia10. Eastell R, Baumann M, Hoyle N, Wieezorek L (eds) (2001) Bone markers, bio-
ehemical and clinical perspeetives. Martin Dunitz, London11. Favus MJ (ed) (1999) Primer on the metabolie bone diseases and disorders of
mineral metabolism. Lippincott, Philadelphia12. Fleisch H (2000) Bisphosphonates in bone disease. 4thedn, Aeademie Press, San
Diego13. Frisch B, Bart! R (1998) Biopsy interpretation of bone and bone marrow. Ar-
nold, London14. Geusens P (ed) (1998) Osteoporosis in clinical praetice. Springer, Berlin, Heidel-
berg, New York,Tokio15. Henderson JE, Goltzman D (eds) (2000) The osteoporosis primer. Cambridge
University Press, Cambridge16. Heuek A (1997) Radiologie der Knochen- und Gelenkerkrankungen. Thierne,
Stuttgart17. Hodgson S (2003) Mayo Clinic on osteoporosis. Mayo Clinic, Rochester18. Hosking D,Ringe J (2000) Treatment of metabolie bone disease - management
strategy and drug therapy. Martin Dunitz, London19. Kleerekoper M,Siris E,MeClung M (eds) (1999) The bone and mineral manual.
Aeademic Press, London20. Mareus R, Feldman D, Kelsey J (eds) (1996) Osteoporosis. Aeademic Press, San
Diego21. Martin B, Burr D, Sharkey N (eds) (1998) Skeletal tissue meehanics. Springer,
Berlin, Heidelberg, New York,Tokio22. Meunier PI (1998) Osteoporosis: diagnosis and management. Martin Dunitz,
London23. MeIlwain H, Bruee D (1999) The osteoporosis eure. Avon Books, New York24. Mareus R (1996) Osteoporosis. Aeademic Press, San Diego25. Mundy G (1999) Bone remodelling and its disorders. 2nd edn , Martin Dunitz,
London26. Notelovitz M (1999) Osteoporosis: prevention, diagnosis and management. Pro-
fessional Communications, Caddo
literatur 221---------
27. Orwoll E (ed) (1999) Osteoporosis in men.Academic Press, San Diego28. Riggs B,Melton L (1995) Osteoporosis Etiology, Diagnosis and Management. 2nd
ed, Lippincott-Raven, Philadelphia29. Ringe J (2003) Osteoporose Dialog . Thieme, Stuttgart30. Ringe J, Meunier P (1996) Osteoporotic fractures in the elderly. Thieme, Stutt-
gart31. Rosen C, Glowack i J, Bilzikian J (eds) (1999) The aging skeleton. Academic
Press, San Diego32. Rubens R,Mundy G (eds) (2000) Cancer and the skeleton. Martin Dunitz, Lon-
don33. Seibel M, Stracke H (1997) Metabolische Osteopathien. Schattauer, Stuttgart34. Wolff J (1986) The law of bone remodelling. Springer, Berlin, Heidelberg, New
York, Tokio35. Woolf A (1994) Osteoporosis. Martin Dunitz, London
Ausgewählte Artikel aus Zeitschriften,geordnet nach Kapiteln
Einführung
1. Browner W,Pressman A, Nevitt M, Cummings S (1996) Mortality following frac-tures in older women. The Study of Osteoporotic Fractures. Arch Intern Med156:521-525
2. Hollon M, Larson E, Koepsell T, Downer A (2003) Direct-to-consumer marke-ting of osteoporosis drugs and bone densitometry. Ann Pharmacother 37:976-981
3. [ohnell 0 (2003) Economic implication of osteoporotic spine disease: cost to so-ciety. Eur Spine J 12:168-169
4. Kado D, Browner E, Palermo L et a!. (1999) Vertebral fractures and mortality inolder women: a prospective study. Arch Intern Med 159:1215-1220
5. Klift M, Laet C, Coebergh J et a!. (2003) Bone mineral density and the risk ofbreast cancer: the Rotterdam study. Bone 32:211-216
6. Levy P, Levy E, Audran M et a!. (2002) The cost of osteoporosis in men: theFrench situation. Bone 30:631-636
7. Lippuner K,von Overbeck J, Perrelet R et a!. (1997) Incidence and direct medi-cal costs ofhospitalisations due to osteoporotic fractures in Switzerland. Osteo-porosis Int 7:414-425
8. Philips S, Fox N, Iacobs J, Wright E (1988) The direct medical costs of os teopo-rosis of American women aged 45 and older. Bone 9:217-219
9. Richmond J,Aharonoff G, Zuckerman J, Koval K (2003) Mortality risk after hipfracture. J Orthop Trauma 17:2-5
10. Saw S-M, Hong C-Y,Lee J eta!. (2003) Awareness and health beliefs of women to-wards osteoporosis. Osteoporos Int 14:595-601
11. Schürch MA, Rizzoli R, Mermillod B et a!. (1996) A prospective study on soci-oeconomic aspects of fracture of the proximal femur. J Bone Miner Research11:1935-1942
222 Literatur----- ----
2 Biologie
1. Ahlborg H, [ohnell 0, Turner C et al. (2003) Bone loss and bone size after me-nopause. Engl J Med 349:327-334
2. Ammann P,Rizzoli R (2003) Bone strength and its determinants. 14 (SuPpI3):13- 18
3. Banse X (2002) When density fails to predict bone strength. Acta Orthop Scand73 (SUPpI303):2-53
4. Bauer D (2003) HMG CoA reductase inhibitors and the skeleton : a comprehen-sive review. Osteoporos Int 14:273-282
5. Boivin G, Meunier P (2003) The mineralisation of bone tissue: a forgotten di-mension in osteoporosis research. Osteoporos Int 14 (SuPpI3):l9-24
6. Bone C, Einhorm T (2003) Overview of osteoporosis: pathophysiology and de-terminants of bone strength. Eur Spine J 12:90-96
7. Bonewald L (2003) Osteocyte biology. Curr Opin Orthop 14:311-3168. Bouxsein M (2003) Bone quality: where do we go from here? Osteoporos Int
14:118-1279. Boyle W, Simonet W, Lacey D (2003) Osteoclast differentiation and activation.
Nature 423:337-34110 . Brumsen C, Papapoulos S, Lentjes E et al. (2002) A potential role for the mast
cell in the pathogenesis of idiopathic osteoporosis in men. Bone 31:556-56111. Buckalter J,Glimcher M, Cooper R, Recker R (1995)Bone biology: Part I: Struc-
ture, blood supply, cells, matrix and mineralisation. J Bone Joint Surg 77A:1256-1275
12. Burr D (2002) The contribution of the organic matrix to bone's material pro-perties. Bone 31:8-11
13. Currey J (2003) Perspective: How well are bones designed to resist fracture. JBone Miner Res 18:591-598
14. Donahue H (2000) Gap junctions and biophysical regulation ofbone cell diffe-rentiation. Bone 26:417-422
15. Flier J (2002) Is brain sympathetic to bone? Nature 420:619-62216. Frank G (2003) Role of estrogen and androgen in pubertal skeletal physiology.
Med Pediatr OncoI41 :217-22117. Harada S, Rodan G (2003) Control of osteoblast function and regulation of
bone mass. Nature 423:349-35518.Manolagas S (2000) Birth and death ofbone cells: Basic regulatory mechanis-
ms and implications for the pathogenensis and treatment of osteoporosis. En-docrine Reviews 21:115-137
19. Mukherjee A,Shalet S (2003) Growth hormone replacement therapy (GHRT) inchildren and adolescents: skeletal impact. Med Pediatr OncoI41:235-242
20.Onley R (2003) Regulation of bone mass by growth hormone. Med Pediatr On-coI41:228-234
21. Orwell E (2003) Men, bone and estrogen: unresolved issues. Osteoporos Int14:93-98
22. Reid R (2003) Bisphosphonates: new indications and methods of administrati-on. Curr Opin RheumatoI15 :458-463
23. Seaman E (2003) Reduced bone formation and increased bone resorption: ra-tional targets for the treatment of osteoporosis. Osteoporos Int 14 (Supp13):2-8
literatur 223---------24. Seeman E (2003) Perio steal bone formation - a neglected determinant ofbone
strength. N Engl JMed 349:320-32325.Takeda S, Elefteriou F, Levasseur R et al. (2002) Leptin regulates bone formati-
on via the sympathetic nervous system. CeIl111:305-31726. Turner C (2002) Biomechanics of bone: determinants of skeletal fragility and
bone quality.Osteoporos Int 13:97- 10427. Turner C (2002) Mechanotransduction in skeletal cells. Curr Opin Orthop
13:363-36728. Young M (2003) Bone matrix proteins: the ir function, regulation, and relation-
ship to osteoporosis. Osteoporos Int 14 (SupP13):35-4229. Zaidi M, Blair H, Moonga B et al. (2003) Osteoclastogenesis, bone resorption,
and osteoclast-based therapeutics. JBone Miner Res 18:599-60930. Zaidi M, Moonga B,Sun I et al. (2003) Understanding osteoclast formation and
function: implications for future therapies for osteoporosis. Curr Opin Orthop14:341-350
3 Definition
1. Ahlborg H, Iohnell 0, Turner C et al. (2003) Bone loss and bone size after me-nopause. Engl JMed 349:327-334
2. Bouxsein M (2003) Bone quality: where do we go from here? Osteoporos Int14:118-127
3. Chavassieux P,Arlot M, Reda C,Wei L,YatesA, Meunier P (1997)Histomorpho-metric assessment of the long-term effects of alendronate on bone quality andremodeling in patients with osteoporosis. JClin luvest 1000:1475-1480
4. Currey J (2003) Perspective: How weil are bones designed to resist fracture. JBone Miner Res 18:591-598
5. Epstein S, InzerilloA, Caminis J, Zaid i M (2003) Review: Disorders associatedwith acute rapid and severe bone loss. JBone Miner Res 18:2083-2094
6. Manolagas S (2000) Birth and death of bone cells: Basic regulatory mechanis-ms and implications for the pathogenensis and treatment of osteoporosis. En-docrine Reviews 21:115-137
7. Port L, Center J, Briffa K et al. (2003) Osteoporotic fracture: missed opportunityfor intervention. Osteoporos Int 14:780-784
8. Sherman P (2003) Osteoporosis and young women. Curr Opin Orthop 14:440-
4449. Stone K, Seeley D, Lui L et al. (2003) BMD at multiple sites and risk of fracture
of multiple types: long-term results from the study of osteoporotic fractures. JBone Miner Res 18:1947-1954
10. Turner C (2002) Biomechanics of bone: determinants of skeletal fragil ity andbone quality. Osteoporos Int 13:97-104
11. Van Staa T,Leufkens H, Cooper C (2002) Does a fracture at one site predict la-ter fractures at other sites ?A british cohort study. Osteoporos Int 13:624-629
12. Van Staa T, Leufkens H, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
13. Young M (2003) Bone matrix proteins: their function, regulation, and relation-ship to osteoporosis. Osteoporos Int 14 (SupP13):35-42
224 literatur----- ----
14. Zaidi M, Blair H, Moonga B et al. (2003) Osteoclastogenesis, bone resorption,and osteoclast-based therapeuties. JBone Miner Res 18:599-609
15. Zaidi M, Moonga B, Sun I et al. (2003) Understanding osteoclast formation andfunction: implications for future therapies for osteoporosis. Curr Opin Orthop14:341-350
4 Risikofaktoren
1. Ahlborg H, [ohnell 0, Turner C et al. (2003) Bone loss and bone size after me-nopause. Engl JMed 349:327-334
2. Ammann P, Rizzoli R (2003) Bone strength and its determinants. 14 (SuPpI3):13-18
3. Biolo G, Heer M, Narici M, Strollo F (2003) Mierogravity as a model of ageing.Curr Opin Clin Nutr Metab Care 6:3-7
4. Bone C, Einhorm T (2003) Overview of osteoporosis: pathophysiology and de-terminants of bone strength. Eur Spine J12:90-96
5. Chapurlat R, Bauer D,Nevitt M et al. (2003) Incidence and risk factors for a sec-ond hip fracture in elderly women. The study of osteoporotie fractures. Osteo -poros Int 14:130-136
6. Chapuy M, Arlot M, Duboeuf F et al. (1992)Vitamin D3 and calcium to preventhip fractures in elderly women. N Engl JMed 327:1637-1642
7. Charles P (1992) Calcium absorption and calcium bioavailability. J Intern Med231:161-168
8. Cohen A, Shane E (2003) Osteoporosis after solid organ and bone marrowtransplantation. Osteoporos Int 14:617-630
9. Cummings S (1996)Treatable and untreatable risk factors for hip fracture. Bone18:165-167
10. Cummings S, Black D, Rubin S (1989) Lifetime risks of hip , Colles ' or vertebralfracture and coronary heart disease among white postmenopausal women.Arch Intern Med 149:2445-2449
11. Ettinger M (2003) Aging bone and osteoporosis: strategies for preventing frac-tures in the elderly. Arch Intern Med 163:2237-2246
12. Fitzpatrick L, Heaney R (2003) Got sodai JBone Miner Res 18:1570-157113. Fleisch H (2001) Can bisphosphonates be given to patients with fracturesi J
Bone Miner Res 16:437-44014. Frank G (2003) Role of estrogen and androgen in pubertal skeletal phys iology.
Med Pediatr OncoI41:217-22115. Gerdhem P, Obrant K (2002) Effects of cigarette-smoking on bone mass as as-
sessed by dual -energy X-ray absorptiometry and ultrasound. Osteoporos Int13:933-936
16. Gerdhem P,Akesson K, Obrant K (2003) Effect of previous and present physiealactivity on bone mass in elderly women. Osteoporos. Int 14:208-212
17. Gourlay M, Riehy F,Reginster J(2003) Strategies for the prevention of hip frac -tures. Am JMed 115:309-317
18. Gregg E, Pereira M, Caspersen C (2000) Physieal activity, falls, and fracturesamong older adults: a review of the epidemiologie evidence. JAm Geriatr Soc48:883-893
literatur 225---------
19. Grisso J,Kelsey J,Strom B et al. (1991) Risk factors for falls as a cause of hip frac-ture in women. N Engl J Med 324:1326-1331
20. Haentjens P,Autier P,Collins J et al. (2003) Colles fracture, spine fracture, andsubsequent risk of hip fracture in men and women. J Bone Joint Surg 85A:1936-
194321. Hughes-Pulford M, Tjandrawinata R, Fitzgerald J et al. (1998) Effects of mic-
rogravity on osteoblast growth. Gravit Space Biol Bull11:51-6022. Kemmler W,Engelke K,Weineck Jet al. (2003) The Erlangen fitness osteoporo-
sis prevention study: a controlled exercise trial in early postmenopausal wom-en with low bone density-first-year results. Arch Phys Med Rehabil84:673-682
23. Klift M, Laet C, Coebergh J et al. (2003) Bone mineral density and the risk ofbreast cancer: the Rotterdam study. Bone 32:211-216
24. Krall E, Dawson-Hughes B (1991) Smoking and bone loss among postmeeno-pausal women. J Bone Miner Res 6:331-338
25. Kudlacek S, Freudenthaler 0 , Weissboeck H et al. (2003) Lactose intolerance: arisk factor for reduced bone mineral density and vertebral fractures? J Gastro-enteroI37:1014-1019
26. Ups P (2001) Vitamin D deficiency and secondary hyperparathyroidism in theelderly: consequences for bone loss and fractures and therapeutic implications.Endocrine Reviews 22:477-501
27. McGartiand C, Robson P, Murray L et al. (2003) Carbonated soft drink con-sumption and bone mineral density in adolescence: the Northern IrelandYoung Hearts Project. J Bone Miner Res 18:1563-1569
28. Perese E, Perese K (2003) Health problems of women with severe mental illness .J Am Acad Nurse Pract 15:212-219
29. Ralston S (2003) Genetic determinants of susceptibility to osteoporosis. CurrOpin PharmacoI3:286-290
30. Recker R, Hinders S,Davies K et al. (1996) Correcting calcium nutritional defi-ciency prevents spine fractures in elderly women. J Bone Miner. Res 11:1961-1966
31. Rehman 0, Lane N (2003) Effect of glucocorticoids on bone density. Med Pedi-atr OncoI41:212-216
32. Reid I, Ames R, Evans M, Gamble G, Sharpe S (1995)Long-term effect of calci-um supplementation on bone loss and fracture in postmenopausal women: arandomized controlled trial. Am J Med 98:331-335
33. Richmond J,Aharonoff G, Zuckerman J, Koval K (2003) Mortality risk after hipfracture. J Orthop Trauma 17:2-5
34. Richy F, Bousquet J, EherIich G et al. (2003) Inhaled corticosteroid effects onbone in asthmatic and COPD patients: a quantitative systematic study. Osteo-poros Int 14:179-190
35. Sambrook P,Kotowicz M, Nash P et al. (2003) Prevention and treatment of glu-cocorticoid-induced osteoporosis: a comparison of Kalzitriol, vitamin D pluscalcium and alendronate plus calcium. J None Miner Res 18:919-924
36. Schuh T, Lyles K (2003) Osteoporosis considerations in the frail elderly. CurrOpin RheumatoI15:481-486
37. Shabat S,Gepstein R, Mann G et al. (2003) The second hip fracture - an analysisof 84 elderly patients. J Orthop Trauma 17:613-617
38. Siebier T,Shalet S,Robson H. (2002) Effects of chemotherapy on bone metabol-ism and skeletal growth. Horm Res 58 (Supph):80-85
226 Literatur----- ----
39. Sinake M (2003) Critical appraisal of physical rehabilitation measures afterosteoporotic vertebral fracture. Osteoporos Int 14:773-77 9
40.Sirola J,Kröger H, Honkanen R et al. (2003) Smoking may impair the bone pro-tective effects of nutritional calcium: a population-based approach. JBone Mi-ner Res 18:1036-1042
41. Smith I, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med348:2431-2442
42.Smith S,Heer M (2002) Calcium and bone metabolism during space flight. Nu-trition 18:849-852
43.Sowers M, Crutchfield M, [annausch M et al. (1991) A prospective evaluation ofbone mineral changee in pregnancy. Obstet Gynecol77:841-845
44.Stone K, Seeley D, Lui L et al. (2003) BMD at multiple sites and risk of fractureof multiple types : long-term results from the study of osteoporotic fractures. JBone Miner Res 18:1947-1954
45. Van Staa T, Leufkens H, Cooper C (2002) Does a fracture at one site predict la-ter fractures at other sites? A british cohort study. Osteoporos Int 13:624-629
46. Van Staa T, Leufkens H, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
47. Verrotti A, Greco R Latini G et al. (2002) Increased bone turnover in prepuber-tal, pubertal and postpubertal patients receiving carbamazepine. Epilepsia43=1488-1492
48. Women's Health Initiative Group (2002) Risks and benefits of estrogen plusprogestin in healthy postmenopausal women. JAMA288:321-333
5 Diagnostik
1. Ahlborg H, Iohnell 0, Turner C et al. (2003) Bone loss and bone size after me-nopause. Engl J Med 349:327-334
2. Banse X (2002) When density fails to predict bone strength.Acta Orthop Scand73 (SuPpI3 03):2-53
3. Bart! R, Bart! C, Mutschier W (2003) Diagnostik und Therapie der Osteoporo-se: Strategie für eine effiziente Prävention von Folgefrakturen. Unfallchirurg106:526-541
4. Baur A, Stäbler A, Arbogast S et al. (2002) Acute osteoporotic and neoplasticvertebral compression fractures: fluid sign at MR imag ing. Radiology 225:730-
7355. Bone C, Einhorm T (2003) Overv iew of osteoporosis: pathophysiology and de-
terminants of bone strength. Eur Spine J 12:90-966. Damilakis J, Papadokostakis G, Perisinakis K et al. (2003) Can radial bone mi-
neral density and quantitative ultrasound measurements reduce the number ofwomen who need axial dens ity skeletal assessment? Osteoporos Int 14:688-693
7. Eddy D,[ohnston C, Cummings S et al. (1998) Osteoporosis: review of the evid-ence for prevention, diagnosis, treatment, and cost -effectiveness analysis.Osteoporos Int 8:7-80
8. Follin S,Black J,McDermott M (2003) Lack of diagnosis and treatment of osteo -porosis in men and women after hip fracture. Pharmacotherapy 23:190-198
9. Harper K, Weber T (1998) Secondary osteoporosis. Diagnostic cons iderations.Endocrinol Metab C!in North Am 27:325-348
literatur 227
10. lohneil 0, Oden A, De Laet C et al. (2002) Biochemieal markers and the assess-ment of fracture probability. Osteoporos Int 13:523-526
11. Iohnell 0, Karmus P,Obrant K et al. (2001) Management of the patient after anosteoporotie fracture: guidelines for orthopedie surgeons. Acta Orthop Scand72:325-330
12. Kanis J,Black D, Cooper C et al. (2002) A new approach to the development ofassessment guidelines for osteoporosis. Osteoporos Int 13:527-536
13. Kullenberg R,Falch J (2003) Prevalence of osteoporosis using bone mineral me-asurements at the calcaneus by dual X-ray and laser (DXL). Osteoporos Int14:823-827
14. Lane J,Gardner M,Lin J et al. (2003) The aging spine : new technologies and the-rapeuties for the osteoporotie spine. Eur Spine J 12:147-154
15. Marshall D, Iohnell 0, Wedel H et al. (1996) Meta-analysis ofhow weil measuresofbone mineral density prediet occurrence of osteoporotie fractures. Br Med J312:1254-1259
16. Mattson J,Cerutis D, Parrish L (2002) Osteoporosis: a review and its dental im-plication. Compend Contin Educ Dent 23:1001-1004
17. O'Gradaigh D,Debiram I, Love S et al. (2003) A prospective study of discordan-ce in diagnosis of osteoporosis using spine and proximal femur bone densito-metry. Osteoporos Int 14:13-18
18.Stone K, Seeley D, Lui L et al. (2003) BMD at multiple sites and risk of fractureof mult iple types: long-term results from the study of osteoporotie fractures. JBone Miner Res 18:1947-1954
19. Szulc P, Delmas P (2001) Biochemical markers of bone turnover in men. CalcifTissue Int 69:229-230
20.Taguchi A,Sanada M, Krall E et al. (2003) Relationship between dental panora-mie radiographie finding s and biochemieal markers of bone turnover. J BoneMiner Res 18:1689-1694
6 Prävention
1. Aharonoff G,Dennis M, Eishinawy A et al. (2003) Circumstances offalls causinghip fractures in the elderIy. J Orthop Trauma 17:22-26
2. Ammann P, Rizzoli R (2003) Bone strength and its determinants. 14(SuPpI3):13-18
3. Chapuy M, ArIot M, Duboeuf F et al. (1992)Vitamin D3 and calcium to preventhip fractures in elderIy women. N Engl J Med 327:1637-1642
4. CharIes P (1992) Calcium absorption and calcium bioavailablility. J Intern Med231:161-168
5· Dawson-Hughes B, Harris S, Krall E, Dallal G (1997) Effect of calcium and vit -amin D supplementation on bone density in men and women 65years of age orolder. N Engl J Med 337:1437-1443
6. Einhorn T,Bonnarens F, Burstein A (1986) The contributions of dietary proteinand mineral to the healing of experimental fractures: a biomechanieal study. JBone Joint Surg Am 68:1389-1395
7. Ettinger M (2003) Aging bone and osteoporosis: strategies for preventing frac -tures in the elderIy. Arch Intern Med 163:2237-2246
8. Fitzpatriek L,Heaney R (2003) Got soda? J Bone Miner Res 18:1570-1571
228 literatur----- ----9. Gerdhem P,Obrant K (2002) Effects of cigarette-srnoking on bone mass as as-
sessed by dual -energy X-ray absorptiometry and ultrasound. Osteoporos Int13:933-936
10. Gerdhem P,Akesson K, Obrant K (2003) Effect of previous and present physiealactivity on bone mass in elderly women. Osteoporos. Int14:208-212
11. Gourlay M, Riehy F,Reginster J (2003) Strategies for the prevention of hip frac-tures. Am J Med 115:309-317
12. Gregg E, Pereira M, Caspersen C (2000) Physieal activity, falls, and fracturesamong older adults: a review of the epidemiologie evidence. J Am Geriatr Soc
48:883-89313. Kannus P, Parkkari J,Niemi s et al. (2000) Prevention ofhip fracture in elderly
people with use of a hip protector. N Engl JMed 343:1506-151314. Katzman D (2003) Osteoporosis in anorexia nervosa: a brittle future? Curr
Drug Target CNS Neurol Disord 2:11-1515. Kemmler W,Engelke K,Weineck Jet al. (2003) The Erlangen fitness osteoporo-
sis prevention study: a controlled exercise trial in early postmenopausal wom -en with low bone density-first-year results .Arch Phys Med Rehabil84:673-682
16. Kudlacek S, Freudenthaler 0, Weissboeck H et al. (2003) Lactose intolerance: arisk factor for reduced bone mineral density and vertebral fractures? J Gastro-enteroI37:1014-1019
17. Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in theelderly: consequences for bone loss and fractures and therapeutie imp!ications.Endocrine Reviews 22:477-501
18. Lips P, Graafmans W, Ooms M, et al. (1996) Vitamin D supplementation andfracture incidence in elderly persons. A randomized placebo-controlled trial.Ann Intern. Med. 124:400-406
19. McGartiand C, Robson P, Murray L et al. (2003) Carbonated soft dr ink con-sumption and bone mineral dens ity in adolescence: the Northern IrelandYoung Hearts Project, J Bone Miner Res 18:1563-1569
zo.Melton L, Heaney R (2003) Osteoporosis: Too much medicine? Or too little!Bone 32:327-331
21. Ralston S (2003) Genetie determinants of susceptibility to osteoporosis. CurrOpin PharmacoI3:286-290
22. Recker R, Hinders S, Davies K et al. (1996) Correcting calcium nut ritional defi-ciency prevents spine fractures in elderly women. J Bone Miner. Res 11:1961-
196623. Rehman 0, Lane N (2003) Effect of glucocortieoids on bone density. Med Pedi-
atr OncoI41:212-21624. Reid I, Ames R, Evans M, Gamble G, Sharpe S (1995) Long-term effect of calci-
um supplementation on bone loss and fracture in postmenopausal women: arandomized controlled trial. Am JMed 98:331-335
25. Riehy F, Bousquet J, Eherlieh G et al. (2003) Inhaled cortieosteroid effects onbone in asthmatie and COPD patients: a quantitative systematie study. Osteo-poros Int14:179-190
26. Sambrook P,Kotowiez M, Nash P et al. (2003) Prevention and treatment of glu-cocorticoid-induced osteoporosis: a comparison of Kalzitriol, vitamin D plusKalzium and alendronate plus calcium. J None Miner Res 18:919-924
27. Schuh T, Lyles K (2003) Osteoporosis considerations in the frail elderly. CurrOpin RheumatoI15:481-486
literatur 229---------28. Sirola J,Kröger H, Honkanen R et al. (2003) Smoking may impair the bone pro-
tective effects of nutritional calcium : a population-based approach. J Bone Mi-ner Res 18:1036-1042
29. Smith I, Dowsett M (2003) Aromatase inh ibitors in breast cancer. N Engl J Med348:2431- 244 2
30. Smith S, Heer M (2002) Calcium and bone metabolism during space flight. Nu-trition 18:849-852
31. Womens Health Initiative Group (2002) Risks and benefits of estrogen plusprogestin in healthy postmenopausal women. JAMA288:321-333
7 Therapie
1. Bagger Y, Tank6 L,Alexandersen P et al. (2003) Alendronate has a residual effecton bone mass in postmenopausal Danish women up to 7 years after treatmentwithdrawal. Bone 33:301-307
2. Barrett-Connor J,Grady D,Sashegyi A et al. (2002) Raloxifene and cardiovascu-lar events in osteoporotic postmenopausal women. Four-year results from theMORE (Multiple Outcomes of Raloxifene Evaluation) randomized tria l. JAMA287:847-857
3. Bart! R (2002) Osteoporose: Was ist gesichert in der Therapie? Internist43:1529-1543
4. Bart! R, Bart! C, MutschIer W (2003) Diagnostik und Therapie der Osteoporo-se: Strategie für eine effiziente Prävention von Folgefrakturen. Unfallchirurg106:526-541
5. Bauer D (2003) HMG CoA reductase inhibitors and the skeleton: a comprehen-sive review. Osteoporos Int 14:273-282
6. Black D, Greenspan S, Ensrud K et al. (2003) The effects of parathyroid hormo-ne and alendronate alone or in combination in postmenopausal osteoporosis.N Engl J Med 349:1207-1215
7. Black D,Thompson D, Bauer D et al. (2000) Fracture risk reduction with alen-dronate in women with osteoporosis:The Fracture Intervention Trial. J Clin En-docrinol Metab 85:4118-4124
8. Black D, Cummings S, Karpf D et al. (1996) Randomised trial of effect of alen-dronate on risk of fracture in women with existing vertebral fractures. Lancet348:1535-1541
9. Black L, Iones C, Falcone J (1983) Antagonism of estrogen action with a newbenzothiophene derived antiestrogen. LifeSei 32:1031-1036
10. Bone H, Adami S, Rizzoli R et al. (2000) Weekly administration of alendronate:rationale and plan for clinical assessment. Clinical Therapeutics 22:15-28
11. Borah B, Dufresne T, Chmielewski P et al. (2002) Risedronate preserves trabe-cular architecture and increases bone strength in vertebra of ovariectomizedminipigs as measured by three-dimensional microcomputed tomography. JBone Miner Res 17:1139-1147
12. Brumsen C,Hamdy N, Papapoulos S (1997) Long-term effects ofbisphosphona-tes on the growing skeleton. Stud ies of young patients with severe osteoporosis.Medicine 76:266- 283
230 Literatur----- ----13. Cauley J,Norton L,Lippman M et al. (2001) Continued breast cancer risk reduc-
tion in postmenopausal women treated with raloxifene: 4-year results from theMORE trial. Breast Cancer Research and Treatment 65:125-134
14. Chapuy M,Arlot M, DuboeufF et al. (1992)Vitamin D3 and calcium to preventhip fractures in elderly women. N Engl J Med 327:1637-1642
15. Chavassieux P, Arlot M, Reda C,Wei L,YatesA, Meunier P (1997)Histomorpho-metric assessment of the long-term effects of alendronate on bone quality andremodeling in patients with osteoporosis. J Clin Invest 1000:1475-1480
16. Chesnut C, Silverman S, Andriano K et al. (2000) A randomized trial of nasalspray salmon calcitonin in postmenopausal women with established osteopo-rosis : the prevent recurrence of osteoporotic fractures study. Am J Med109:267- 276
17. Chesnut C, McClung M, Ensrud K et al. (1995) Alendronate treatment of thepostmenopausal osteoporotic women: effect of multiple dosages on bone massand bone remodeling.Am J Med 99:144-152
18. Cranney A, Guyatt G, Griffith L et al. (2002) IX: Summary of meta-analyses oftherapies for postmenopausal osteoporosis. Endocrine Reviews 23:570-578
19. Cummings S,Eckert S,Krueger K et al. (1999) The effect of raloxifene on risk ofbreast cancer in postmenopausal women. JAMA281:2189-2197
20. Cummings S, Black D Thompson D et al. (1998) Effect of alendronate on risk offracture in women with low bone density but without vertebral fractures. JAMA280:2077-2082
21. Dawson-Hughes B, Harris S, Krall E, Dallal G (1997) Effect of calcium and vit-amin D supplementation on bone density in men and women 65years of age orolder. N Engl J Med 337:1437-1443
22. Dempster D, Cosman F,Kurland E et al. (2001) Effects of daily treatment withparathyroid hormone on bone microarchitecture and turnover in patients withosteoporosis: a paired biopsy study. J Bone Miner. Res 16:1846-1853
23. Ettinger B,Black D,Mitlak Bet al. (1999) Reduction of vertebral fracture risk inpostmenopausal women with osteoporosis treated with raloxifene. Resultsfrom a 3-year randomised clinical trial. JAMA282:637-645
24. Finkelstein J,Hayes A, Hunzeiman J et al. (2003) The effects of parathyroid hor-mone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
25. Fleisch H (2003) Bisphosphonates in osteoporosis. Eur Spine J 12:142-14626. Freedman K,Kaplan F,Bilker w et al. (2000 ) Treatment of osteoporosis: are phy-
sicians missing an opportunity?J Bone Joint Surgery 82:1063-107027. Gandrud L, Cheung J,Daniels M, Bachrach L (2003) Low-dose intravenous pa-
midronate reduces fractures in childhood osteoporosis. Pediatr EndocrinolMetab 16:887-892
28.Glasebrook A, Short L, Cole H et al. (1995) Regulation of serum IL-6 by raloxi-fene in an OVX rat model. Bone 16:99S
29.Glorieux F,Bishop N,Plotkin H et al. (1998)Cyclical administration of pamidro-nate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
30. Grady D (2003) Postmenopausal hormones - therapy for symptoms only. NEngl J Med 348:1835-1837
31. Haguenauer D,Welch V,Shea B et al. (2000) Fluoride for the treatment of post-menopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727-738
literatur 231---------
32. Harris S,Watts N,Genant G et al. (1999) Effects ofrisedronate treatment on ver-tebral and nonvertebral fractures in women with postmenopausal osteoporo-sis. JAMA282:1344-1352
33. Häuselmann H, Rizzoli R (2003) A comprehensive review of treatments forpostmenopausal osteoporosis. Osteoporos Int 14:2-12
34. Heinemann D (2000) Osteoporosis. An overview of the National OsteoporosisFoundation clinical practice guide . Geriatrics 55:31-36
35. HiIner B,Ingle J, Chelbowski R,et al. (2003) American Society of Clinical Onco-logy 2003 update on the role of bisphosphonates and bone health issues inwomen with breast cancer. Clin OncoI21:4042-4057
36. Hochberg M,Greenspan S,Wasnich R et al. (2002) Changes in bone density andturnover explain the reduction in incidence of nonvertebral fractures that oc-cur during treatment with antiresorptive agents . J Clin Endocrinol Metab87:1586-1592
37. Hornby SB,Evans G, Hornby SL et al. (2003) Leng-term zoledronic acid treat-ment increases bone structure and mechanical strength of long bones of ovar-ectomized adult rats. Ca1cifTissue Int 72:519-527
38. Hosking D, Chilvers C, Christiansen C et al. (1998)Prevention ofbone loss withalendronate in postmenopausal women under 60 years of age. N Engl J Med338:485-492
39. Jiang Y, Zhao J,Mitlak B et al. (2003) Recombinant human parathyroid hormo-ne (1-34» [teriparatide] improves both cortical and cancellous bone structure.J Bone Miner Res 18:1932-1941
40.Kanis J, Black D,Cooper C et al. (2002) A new approach to the development ofassessment guidelines for osteoporosis. Osteoporos Int 13:527-536
41. Khosla S (2003) Parathyroid hormone plus alendronate - a combination thatdoes not add up. N Engl J Med 349:1277-1279
42. Liberman U, Weiss S, Bröll Jet al. for the Alendronate Phase III OsteoporoisTreatment Study Group (1995) Effect of oral alendronate on bone mineral den-sity and the incidence of fractures in postmenopausal osteoporosis. N Engl JMed 333:1437-1443
43. Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in theelderly : consequences for bone loss and fractures and therapeutic implications.Endoc rine Reviews 22:477-501
44.Lips P, Graafmans W, Ooms M, et al. (1996) Vitamin D supplementation andfracture incidence in elderly persons. A randomized placebo-controlled trial.Ann Intern. Med. 124:400-406
45. Marcus R, Wong M, Heath H et al. (2002) Antiresorptive treatment of postme-nopausal osteoporosis: comparison of study designs and outcomes in largeclinical trials with fracture as an endpoint. Endocrine Reviews 2}:16-37
46.Marieie M,Aachi J,Meunier Pet al. (2000) Raloxifene 60 mg/day has effects wi-thin 12months in postmenopausal osteoporosis treatment and prevention stu -dies. Arthritis Rheum 43 (SuPpI9):197-201
47. Marie P (2003) Optimizing bone metabolism in osteoporosis: insight into thepharmacologic profile of strontium ranelate. Osteoporos Int 14 (SuPpI3) :9-12
48.Masud T, Mu1cahy B, Thompson AV et al. (1998) Effects of cyclical etidronatecombined with ca1citrol versus cyclical etidronate alone on spine and femoralneck bone mineral density in postmenopausal osteoporotic women. AnnRheum Dis 57:346- 349
232 literatur----- ----
49.McClung M, Wasnich R, Recker R et al. (2004) Oral daily ibandronate preventsbone loss in early postmenopausal women without osteoporosis. J Bone MinerRes 19:11-18
50. McClung M, Eastell R, Benhamouu L et al. (2001) Risedronate reduces hip frac-tures in elderly postmenopausal women. N Engl J Med 344:333-340
51. Melton L, Heaney R (2003) Osteoporosis: Too much medicine? Or too little ?Bone 32:327-331
52. Migliaccio S, Anderson J (2003) Isoflavones and skeletal health: are these rno-lecules ready for clinical application? Osteoporos Int 14:361-368
53. Minne H, Pfeifer M (2003) Evidenzbasierte Therapie der Osteoporose. DtschMed Wochens chr 128:931-934
54. Mosca L, Barrett-Connor E, Wenger N et al. (2001) Design and methods of theRaloxifene Use for The Heart (RUTH) study. Am J CardioI88:392-395
55. Mukherjee A,Shalet S (2003) Growth hormone replacement therapy (GHRT) inchildren and adolescents: skeletal impact. Med Pediatr Oncol 41:235-242
56. Neer R, Arnaud C, Zanchetta J et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women withosteoporosis. N Engl J Med 344:1434-1441
57. Nordin C (2003) Should the treatment of osteoporosis be more selective? Osteo-poros Int 14:99-102
58.0rwoll E (2003) Men, bone and estrogen: unresolved issues . Osteoporos Int14:93-98
59. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment ofosteoporosis in men . N Engl J Med 343:604-610
öo.Pasco J, Henry M, Sanders K et al. (2004) Beta-adrenergic blockers reduce therisk of fracture partly by increasing bone mineral density: Geelong Osteoporo-sis Study. J Bone Miner Res 19:19-24
61. Peter C, Cook W, Nunamaker D et al. (1996) Effect of alendronate on fracturehealing and bone remodeling in dogs . JOrthop Res 14:74-79
62. Pfeifer M, Lehmarm R, Minne H (2001) Die Therapie der Osteoporose aus demBlickwinkel einer auf Evidenz bas ierenden Medizin. Med Klin 96:270-280
63. Pols H, Felsenberg D, Hanley D, et al. (1999) Multinational, placebo-controlled,randomized trial of the effects of alendronate on bone density and fracture riskin postmenopausal women with low bone mass: results of the FOSIT study.Osteoporos Int 9:461-468
64. Rao R, Singrakhia M (2003) Current concepts review: painful osteoporotic ver-tebral fracture. JBone Joint Surg 85:2010-2022
65. Ravn P,Neugebauer G, Christiansen C (2002) Association between pharmaco-kinetics of oral ibandronate and clinical response in bone mass and bone turn-over in women with postmenopausal osteoporosis. Bone 30:320-324
66. Reginster J,Meunier P (2003) Strontium ranelate phase 2 dose-ranging studies:PREVOSand STRATOS studies. Osteoporos Int 14 (SUPpI3):56-65
67. Reginster J, Minne H, Sorensen 0 et al. (2000) Randomized trial of the effectsof risedronate on vertebral fractures in women with established postmenopau-sal osteoporosis. Osteoporos Int 11:83-91
68. Reid I, Brown J,Burckhardt P et al. (2002) Intravenous zoledronic acid in post-menopausal women with low bone mineral density. N Engl J Med 346:653-661
69.Reid I,Ames R, Evans M, Gamble G, Sharpe S (1995) Long-term effect of calci-
literatur 233---------um supplementation on bone loss and fracture in postmenopausal women: arandomized controlled trial. Am J Med 98:331-335
70.Reid R (2003) Bisphosphonates: new indieations and methods of administrati-on. Curr Opin RheumatoI15 :458-463
71. Ringe J,Niekelsen T (2003) Rekonstruktion osteoporotischen Knochengewebesmit Teriparatid. Arzneimitteltherapie 21:194-199
72. Ringe J,Dorst A, Faber H et al. (2003) Three-monthly ibandronate bolus injec-tion offers favourable tolerability and sustained efficacy advantage over twoyears in established cortieosteroid-induced osteoporosis. Rheumatology 42:
743-749n Rodan G, Martin T (2000) Therapeutic approaches to bone diseases . Science
289:1508-151474. Roschger P, Rinnerthaler S, Yates J et al. (2001) Alendronate increases degree
and uniformity of mineralisation in cancellous bone and decreases the porosityin cortical bone of osteoporotie women. Bone 29:185-191
75. Rosen C, Bilezikian J (2001) Anabolie therapy of osteoporosis. J Clin Endocri-nol Metab 86:957-964
76.Rosen C, Black D, Greenspan S (2004) Perspective: Vignettes in osteoporosis: aroad map to successful therapeuties. J Bone Miner Res 19:3-10
n. Rubin M., Cosman F,Lindsay R,Bilezikian J (2002) The anabolie effect of para-thyroid hormone. Osteoporos Int 13:267-277
78. Saag K, Emkey R, Schnitzer T et al. (1998)Alendronate for the treatment of glu-cocortieoid-induced osteoporosis. N Engl J Med 339:292-299
79. Sambrook P,Kotowiez M, Nash P et al. (2003) Prevention and treatment of glu-cocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D pluscalcium and alendronate plus calcium . J None Miner Res 18:919-924
Bo.Santini D, Vespasiani G,Vincenti B (2003) The antineoplastic role of bisphos-phonates: from basie research to clinical evidence.Ann OncoI14:1468-1476
81. Sato M, Glasebrook A,Bryant H (1994) Raloxifene: a selective estrogen receptormodulator. J Bone Miner Metab 12:9-20
82.Scrammel B (1999) Alendronate prevents periprosthetie bone loss - 2 year re-sults. J Bone Mineral Res 14 (Supplrujat
83. Seaman E (2003) Reduced bone formation and increased bone resorption: ra-tional targets for the treatment of osteoporosis. Osteoporos Int 14 (Supp!3):2-8
84.Siminoski K, Fitzgerals A, Flesch G et al. (2000) Intravenous pamidronate fortreatment of reflex sympathetie dystrophy during breast feeding. J Bone MinerRes 15:2052-2055
85.Stakkestad J, Benevolenskaya L,Stepan J et al. (2003) Intravenous ibandronateinjections given every three months: a new treatment option to prevent boneloss in postmenopausal women. Ann Rheum Dis 62:969-975
86.Thiebaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intrave-nous injections of ibandronate in the treatment of postmenopausal osteoporo-sis. Am J Med 103=298-307
87.Tonino R, Meunier P, Emkey R et al. (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Me-tab 85:3109-3115
88.Torgenson D, Bell-Seyer S (2001) Hormone replacement therapy and preven-tion of nonvertebral fractures: a meta-analysis of randomized trials . JAMA285:2891-2897
234 Literatur----- ----89. Van Schoor N,Deville W,Bouter L et al. (2002) Acceptance and compliance with
external hip protectors: a systematic review of the literature. Osteoporos Int13:917-924
90.Watts N, Harris S, Genant H et al. (1990) Intermittent cyclical etidronate treat-ment of postmenopausal osteoporosis. N Engl J Med 323:73-79
91. Women 's Health Initiative Group (2002) Risks and benefits of estrogen plusprogestin in healthy postmenopausal women. JAMA288:321-333
92. Yang N, Hardicar S (1994) Estrogen receptor: two ligands, two transcriptionpathways. J Bone Miner Res 9:144
93. Yang N, Bryant H, Hardicar S et al. (1996) Estrogen and raloxifene stimulatetransforming growth factor-ßj gene express ion in rat bone: a potential mecha-nism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology137:2075-2084
94.YangN, Hardicar S, Kim J,Sato M (1993) Raloxifene, an "anti-estrogen" stimu-lates the effects of estrogen on inhibiting bone resorption through regulatingTGFß3 expression in bone. J Bone Miner Res 8:118
95. Zaidi M, Moonga B,Sun I et al. (2003) Understanding osteoclast formation andfunction: implications for future therapies for osteoporosis. Curr Opin Orthop14:341-350
96.Zuckerman S, Bryan N (1996) Inhibition of LDLoxidation and myeloperoxida-se-dependent tyrosyl radical formation by the selective estrogen receptor mo-dulator raloxifene (LY139481 HCI).Atherosclerosis 126:65-75
8 Sonderformen
1. Bailey D (1997)The Saskatchewan pedriatic bone mineral accrual study: bonemineral acquisition during the growing years . Int J Sports Med 18(SuPpI3):191-194
2. Bauer TW,Schils J (1999) The pathology of total joint arthroplasty - I. Mecha-nisms of implant fixation . Skeletal Radiol 28:423-432
3. Bauer TW,Schils J (1999) The pathology of total joint arthroplasty - 11. Mecha-nisms of implant failure. Skeletal RadioI28:483-497
4. Borderi M, Farneti B,Tampellini L et al. (2002) HIV-l, HAARTand bone meta-bolism. New MicrobioI25 :375-384
5. Brumsen C,Hamdy N, Papapoulos S (1997) Long-term effects ofbisphosphona-tes on the growing skeleton . Studies of young patients with severe osteoporosis.Medicine 76:266-283
6. Cohen A, Shane E (2003) Osteoporosis after solid organ and bone marrowtransplantation. Osteoporos Int 14:617-630
7. Cummings S,Black D, Rubin S (1989) Lifetime risks of hip, Colles ' or vertebralfracture and coronary heart disease among white postmenopausal women.Arch Intern Med 149:2445-2449
8. Epstein S, InzerilloA , Caminis J, Zaidi M (2003) Review: Disorders associatedwith acute rapid and severe bone loss. J Bone Miner Res 18:2083-2094
9. EI-Shinnawi U, EI-Tantawy S (2003) The effect of alendronate sodium on alveo-lar bone loss in periodontitis (clinical trial). J Int Acad Periodontol yy-ro
10. Emkey R, Delmas P,Goemaere S et al. (2003) Changes in bone mineral density
literatur 235---------
following discontinuation of alendronate therapy of glucocortieoid-treated pa-tients: a retrospective, observational study. Arthritis Rheum 48:1102-1108
11. Finkelstein J,Hayes A, Hunzeiman J et al. (2003) The effects of parathyroid hor-mone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
12. Follin S, Black J,McDermott M (2003) Lack of diagnosis and treatment of osteo-porosis in men and women after hip fracture. Pharmacotherapy 23:190-198
13. Frank G (2003) Role of estrogen and androgen in pubertal skeletal physiology.Med Pediatr OncoI41:217-221
14. Gandrud L, Cheung J, Daniels M, Bachrach L (2003) Low-dose intravenous pa-midronate reduces fractures in childhood osteoporosis. Pediatr EndocrinolMetab 16:887-892
15. Glorieux F,Bishop N, Plotkin H et al. (1998) Cyclieal adm inistration of pamidro -nate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
16. Glowacki J, Hurwitz S,Thornhill T et al. (2003) Osteoporosis and vitamin-D de-ficiency among postmenopausal women with osteoarthritis undergoing totalhip arthroplasty. J Bone Joint Surg Am. 85A:2371-2377
17. Goodship A, Lawes T,Green J. et al. (1999) Bisphosphonates can inhibit mecha-nieally related loosening of hip prostheses. J Bone Joint Surg (Br) 81-B:Supp III
18. Gourlay M, Riehy F,Reginster J (2003) Strategies for the prevention of hip frac-tures. Am J Med 115:309-317
19. Gruen T, McNeiee G,Amstutz H (1979)"Modes of failure" of cemented stern-ty-pe femoral components: a radiographie analysis of loosening. Clin Orthop141:17-27
20. Haentjens P, Autier P, Collins J et al. (2003) Colles fracture, spine fracture, andsubsequent risk ofhip fracture in men and women. J Bone Joint Surg 85A:1936-
194321. Harper K, Weber T (1998) Secondary osteoporosis. Diagnostie considerations.
Endocrinol Metab Clin North Am 27:325-34822. Hartman C, Hochberg Z, Shamir R (2003) Osteoporosis in pediatries. IMAJ
5:509-51523. Hennings TH (2000) Prophylaxe des periprothetischen Knochenschwundes
durch frühen postoperativen Einsatz von Alendronat - Randomisierte, pro-spektive, kontrollierte 12-Monate follow-up Studie. Osteologie 9:(Supph):75
24. Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P (2000) Clodronate preventsprosthetie migration: a randomized radiostereometrie study of 50 tota l kneepatients. Acta Orthop Scand 71:553-557
25. Hofman S (1999) Bone marrow oedema in transient osteoporosis, reflex sympa-thetie dystrophy and osteonecrosis. EFORT 4:138-151
26. Iwase M, Kim KJ, Kobayashi et al. (2002) A novel bisphosphonate inhibits inf-lammatory bone resorption in a rat osteolys is model with continuous infusionof polyethylene particles. J Orthop Res 20:499-505
27. Katzman D (2003) Osteoporosis in anorexia nervosa: a brittle future? CurrDrug Target CNS Neurol Disord 2:11-15
28. Kerner J, Huiskes R, van Lenthe GH et al. (1999) Correlation between pre-ope-rative periprosthetie bone density and post-operative bone loss in THA can beexpla ined by strain-adaptive remodelling. J Biomech 32:695-703
29. Key L, Ries W, Madyastha P, Reed F (2003) Juvenile osteoporosis: recognizingthe risk. J Pediatr Endocrinol Metab 16 (SuppI3):683-686
236 literatur----- ----30. Köck F,Borisch N, Koester B,Grifka J (2003) Das komplexe regionale Schmerz-
syndrom Typ I (CRPS I): Ursachen, Diagnostik und Therapie. Orthopäde32:418-431
31. Kudlacek S, Freudenthaler 0, Weissboeck H et al. (2003) Lactose intolerance: arisk factor for reduced bone mineral density and vertebral fractures? J Gastro-enteroI37:1014-1019
32. Levy P, Levy E, Audran M et al. (2002) The cost of osteoporosis in men: theFrench situation. Bone 30:631-636
33. Mandelin J,LiT-F, Liljeström M et al. (2003) Imbalance of RANKL/RANK/OPGsystem in interface tissue in loosening of total hip replacement. J Bone JointSurg 85-B:u96-1201
34. Marcus R, Wong M, Heath H et al. (2002) Antiresorptive treatment of postme-nopausal osteoporosis: comparison of study designs and outcomes in largeclinical trials with fracture as an endpoint. Endocrine Reviews 23:16-37
35. Melton III J, Rajkumar V, Khosla S et al. (2004) Fracture risk in monoclonalgammopathy of undetermined sign ificance. J Bone Miner Res 19:25-30
36. Mukherjee A,Shalet S (2003) Growth hormone replac ement therapy (GHRT) inchildren and adolescents: skeletal impact. Med Pediatr OncoI41:235-242
37. Nakashima A,Yorioka N, Tanji C et al. (2003) Bone mineral density may be re-lated to atherosclerosis in hemodialysis pat ients . Osteoporos. Int 14:369-373
38.0rwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment ofosteoporosis in men. N Engl J Med 343:604-610
39. Perese E,Perese K (2003) Health problems of women with severe mental illness .J Am Acad Nurse Pract 15:212-219
40.Rauch F, Plotkin H, Zeitlin L, Glorieux F (2003) Bone mass , size and density inchildren and adoles cence with osteogenesis imperfecta: effect of intravenouspamidronate therapy. J Bone Miner Res 18:610-614
41. Rehman 0, Lane N (2003) Effect of glucocorticoids on bone density. Med Pedi-atr Oncol 41:212-216
42. Reid R (2003) Bisphosphonates: new indications and methods of administrati-on. Curr Opin RheumatoI15:458-463
43. Richy F, Bousquet J, Eherlich G et al. (2003) Inhaled corticosteroid effects onbone in asthmatic and COPD patients: a quantitative systematic study. Osteo-poros Int 14:179-190
44.Ringe J, Dorst A, Faber H et al. (2003) Three -monthly ibandronate bolus injec-tion offers favourable tolerability and sustained efficacy advantage over twoyears in established corticosteroid-induced osteoporosis. Rheumatology 42:
743-74945.Ringe J,Faber H, Dorst A (2001) Alendronate treatment of established primary
osteoporosis in men: results of a 3-year prospective study. J Clin EndocrinolMetab 86:5252-5255
46.Saag K,Emkey R,Schnitzer T et al. (1998)Alendronate for the treatment of glu-cocorticoid-induced osteoporosis. N Engl J Med 339:292-299
47. Santini D,Vespasiani G, Vincenti B (2003) The antineoplastic role of bisphos-phonates: from basic research to clinical evidence.Ann OnCOI14:1468-1476
48. Schwartz A,Sellmeyer D,Ensrud K et al. (2001) Older women with diabetes havean increased risk of fracture: a prospective study. J Clin Endocrinol Metab86:32-38
literatur 237---------
49.Scrammel B (1999) Alendronate prevents periprosthetie bone loss - 2 year re-sults. JBone Mineral Res 14(Supphj.jar
50. Sherman P (2003) Osteoporosis and young women . Curr Opin Orthop 14:440-
44451. Siebier T,Shalet S,Robson H. (2002) Effects of chemotherapy on bone metabol-
ism and skeletal growth. Horm Res 58 (Supph):80-8552. Siminoski K, Fitzgerals A, Flesch G et al. (2000) Intravenous pamidronate for
treatment of reflex sympathetie dystrophy during breast feeding. JBone MinerRes 15:2052-2055
53. Smith I, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl JMed348:2431-2442
54. Sudeck P (1902) Über die akute (trophoneurotoxische) Knochenatrophie nachEntzündungen und Traumen der Extremitäten. Deutsch Med Wochenschr28:336-342
55. Szulc P,Delmas P (2001) Biochemieal markers of bone turnover in men. CalcifTissue Int 69:229-230
56. Taguchi A,Sanada M, Krall E et al. (2003) Relationship between dental panora-mie radiographie findings and biochemieal markers of bone turnover. J BoneMiner Res 18:1689-1694
57. Van Staa T, Leufkens H, Cooper C (2002) The epidemiology of cortieosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
58. Verrotti A, Greco R Latini G et al. (2002) Increased bone turnover in prepuber-tal, pubertal and postpubertal patients receiving carbamazepine. Epilepsia43:1488-1492
59. Wallach S, Cohen S, Reid D et al. (2000) Effects of risedronate treatment onbone dens ity and vertebral fracture in patients on cortieosteroid therapy. Cal-cif Tissue Int 67:277-285
60.Watts N, Harris S, Genant H et al. (1990) Intermittent cyclical etidronate treat-ment of postmenopausal osteoporosis. N Engl JMed 323:73-79
61. Weber T, Drezner M (2001) Effect of alendronate on bone mineral density inmale idiopathie osteoporosis. Metabolism 50:912-915
9 Frakturen
1. Aharonoff G,Dennis M, Eishinawy A et al. (2003) Circumstances of falls causinghip fractures in the elderly. JOrthop Trauma 17:22-26
2. Bachmann D (2003) Osteoporotie patient: what to do after fixing the fracture.Curr Opin Orthop 14:445-449
3. Bagger Y, Tank öL,Alexandersen P et al. (2003) Alendronate has a residual effecton bone mass in postmenopausal Danish women up to 7 years after treatmentwithdrawal. Bone 33=301-307
4. Bart! R (2003) Management der manifesten Osteoporose - eine neue Verant-wortung für den Unfallchirurgen! Unfallchirurg 106:525
5. Bart! R, Bart! C, Mutschier W (2003) Diagnostik und Therapie der Osteoporo-se: Strategie für eine effiziente Prävention von Folgefrakturen. Unfallchirurg106:526-541
238 Literatur----- ----
6. Bestehorn K, Raspe H, Götte S et al. (2002) Berücksichtigung der Osteoporosebei der Therapie nicht -vertebraler Frakturen - Pilotstudie zum FX-Register.(2002) Zeitschr. Rheumatol. 61 (Supp1.I):80
7. Bestehorn K, Zink A, Dreher R et al. (2002) Pharmakotherapie bei postmeno-pausaler Osteoporose. Analyse der Versorgungssituation. Z. ärztI. Fortbild.Qual.sich.96:699-704
8. Brody B, Dickey N, Ellenberg S et al. (2003) Is the use of placebo controls ethi-cally permissible in clinical trials of agents intended to reduce fractures inosteoporosisi J Bone Miner Res 18:1105-1109
9. Chapurlat R, Bauer D, Nevitt M et al. (2003) Incidence and risk factors for a sec-ond hip fracture in elderly women. The study of osteoporotic fractures. Osteo-poros Int 14:130-136
10 . Cho T, Gerstenfeld L, Barnes G, Einhorn T (2003) Cytokines and fracture hea-ling. Current Opinion in Orthopaedics 12:403-408
11. Cree M, [uby A, Carriere K (2003) Mortality and morbidity associated withosteoporosis drug treatment following hip fracture. Osteoporos. Int 14:722-727
12. Currey J (2003) Perspective: How weil are bones designed to resist fracture. JBone Miner Res 18:591-598
13. Ettinger M (2003) Aging bone and osteoporosis: strategies for preventing frac-tures in the elderly. Arch Intern Med 163:2237-2246
14. Feldstein A, Nichols G, Eimer P et al. (2003) Older women with fractures: pati-ents falling through the cracks of guideline - recommended osteoporosisscreening and treatment. J Bone Joint Surg 85A:2294-2302
15. Fleisch H (2001) Can bisphosphonates be given to patients with fractures? JBone Miner Res 16:437-440
16. Follin S,Black J,McDermott M (2003) Lack of diagnosis and treatment of osteo-porosis in men and women after hip fracture. Pharmacotherapy 23:190-198
17. Franck H, Boszczyk B, Bierschneider M, Jaksehe H (2003) Interdisciplinary ap-proach to balloon kyphoplasty in the treatment of osteoporotic vertebral com-pression fractures. Eur Spine J 12:163-167
18. Freedman K, Kaplan F, Bilker W et al. (2000) Treatment of osteoporosis: arephysicians missing an opportunity? J Bone Joint Surg 82A:l063-1070
19. Gardner M, Flik K, Mooar P et al. (2002) Improvement in the undertreatment ofosteoporosis following hip fracture. J Bone Joint Surgery 84:1342-1348
20.Götte S, Dittmar K (2001) Epidemiologie und Kosten der Osteoporose. Ortho-päde 30:402-404
21.Gourlay M, Richy F,Reginster J (2003) Strategies for the prevention ofhip frac-tures. Am J Med 115:309-317
22.Grados F,Depriester C, Cayrolle G et al. (2000) Leng-term observations of ver-tebral osteoporotic fractures treated by percutaneous vertebroplasty. Rheuma-tology 39:1410-1414
23. Haentjens P, Autier P,Collins J et al. (2003) Colles fracture, spine fracture, andsubsequent risk ofhip fracture in men and women. J Bone Joint Surg 85A:1936-1943
24. Heinemann D (2000) Osteoporosis. An overview of the National OsteoporosisFoundation clinical practice guide. Geriatrics 55:31-36
25. [ohnell 0, Kannus P, Obrant K et al. (2001) Management of the patient after anosteoporotic fracture: guidelines for orthopedic surgeons. Acta Orthop Scand72:325-330
literatur 239---------
26. Juby A, De Geus-Wenceslau C (2002) Evaluation of osteoporosis treatment inseniors after hip fracture. Osteoporos Int 13:205-210
27. Kamel H, Hussain M, Tariq S et al. (2000) Failure to diagnose and treat osteo-porosis in elderly patients hospitalized with hip fracture.Amer J Med 109:326-328
28. Kanis J, Iohnell 0, Oden A et al. (2001) Ten year probabilities of osteoporoticfractures according to BMD and diagnostic thresholds. 12:989-995
29. Kannus P, Parkkari J, Niemi s et al. (2000) Prevention of hip fracture in elderlypeople with use of a hip protector. N Engl J Med 343=1506-1513
30. Kaufman J, Bolander M, Bunta A et al. (2003) Barriers and solutions to osteopo-rosis care in patients with a hip fracture. J Bone Joint Surg 85A:1837-1843
31. Kemmler W,Engelke K,Weineck Jet al. (2003) The Erlangen fitness osteoporo-sis prevention study: a controlled exercise trial in early postmenopausal wom-en with low bone density-first-year results. Arch Phys Med Rehabil84:673-682
32. Lane J,Gardner M,Lin J et al. (2003) The aging spine: new technologies and the-rapeutics for the osteoporotic spine. Eur Spine J 12:147-154
33. Martin A, Sornay-Rendu E, Chandler J et al. (2002) The impact of osteoporosison quality-of-life: theOFELYcohort. Bone 31:32-36
34. Namkung-Matthai H, Appleyard R, Iansen J et al. (2001) Osteoporosis inftuen -ces the early per iod of fracture healing in a rat osteoporotic model. Bone 28:80-86
35. Nguyen TV,Center JR, Sambrook PN et al. (2001) Risk factors for proximal hu-merus, forearm, and wrist fractures in elderly men and women: The DubboOsteoporosis Epidemiology Study.Am J EpidemioI153;6:587-95
36. Rao R, Singrakhia M (2003) Current concepts review: painful osteoporotic ver-tebral fracture. J Bone Joint Surg 85:2010-2022
37. Schuh T, Lyles K (2003) Osteoporosis considerations in the frail elderly. CurrOpin RheumatoI15:481-486
38. Schürch MA, Rizzoli R, Mermillod B et al. (1996) A prospective study on soci-oeconomic aspects of fracture of the proximal femur. J Bone Miner Research11:1935-1942
39. Scrammel B (1999) Alendronate prevents periprosthetic bone loss - 2 year re-sults . J Bone Mineral Res 14 (Supphj.ja;
40.Shabat S, Gepstein R, Mann G et al. (2003) The second hip fracture - an analy-sis of 84 elderly patients. J Orthop Trauma 17:613-617
41.Torgerson D,Dolan P (1998) Prescribing by general practitioners after an osteo-porotic fracture. Ann Rheum Dis 57:378-379
42. Van Staa T, Leufkens H, Cooper C (2002) Does a fracture at one site predict la-ter fractures at other sitesi A british cohort study. Osteoporos Int 13:624-629
Osteoporose kompakt
OSTEOPOROSE - Wie diagnostiziere ich richtig?
Diagnostisches Ziel~ Osteoporose ist eine klinische Diagnose, die Knochendichte-
messung stellt nur einen nützlichen Parameter!
Diagnostische Schlüsselfragen~ Wie hoch ist die Knochenmassel~ Liegen bereits Frakturen/Deformierungen vor?~ Sind die Veränderungen noch reversibel?~ Ist eine Osteomalazie ausgeschlossen?~ Welches Risikoprofilliegt vor?~ Liegt eine andere Krankheit zugrunde?
Krankengeschichte~ Familiäre Osteoporose-Belastung?~ Rücken- , Kreuz- und Gelenkschmerzen?~ Vorbestehende Frakturen?~ Östrogensubstitution bereits eingeleitet?~ Knochenschädigende Krankheiten/Medikamente?~ Erstellen eines Risikoprofils
Körperliche Untersuchung~ Körpergröße und deren Abnahme (>4 cm)~ Statik und Körperhaltung~ Bewegungseinschränkungen~ Rundrücken und andere WS-Deformierungen~ Muskeltonus und Muskelverspannungen~ "Steh- und Gehversuch", Refiexsituation~ Zeichen einer sekundären Osteoporose?
242 Osteoporose kompakt---- - ----
Laboruntersuchung (Blut).. Blutbild, BSG,GPT,Glukose, Kreatinin.. Ca,Ph,aP.. (Vitamin D, PTH, TSH, Testosteron)
Bildgebung (Knochendichtemessung).. Röntgen LWS in 2 Ebenen (BWS, HWS):Wirbeleinbrüche = "mani-
feste Osteoporose", Aortenkalkt.. DXA LWS und Hüfte: von der WHO vorgeschriebene Methode zur
Diagnosestellung einer Osteoporose (Standard) , sehr strahlenarm,gleichzeitige Messung von LWS und Hüfte.T-Werte >-1 SD Normalbefund
-1,0 bis -2,5 SD Osteopenie
Osteoporosekompakt 243---------
OSTEOPOROSE - Wie therapiere ich erfolgreich?
Therapeutisches Ziel~ Erreichen einer positiven Knochenbilanz~ Erhöhung der Knochenfestigkeit mit Reduktion des Frakturrisikos
Therapeutische Schlüsselfragen~ Reicht die Basistherapie aus?~ Welche Schmerztherapie ist sinnvoll?~ Ist eine Hormontherapie anzuraten?~ Wann ist Raloxifen vorteilhaft?~ Wann sind Bisphosphonate einzusetzen?~ Welches Bisphosphonat ist vorzuziehen?~ Sind Therapiekombinationen sinnvoll?~ Wie kontrolliere ich den Therapieerfolg?~ Welche Therapiedauer ist ausreichend?
Basistherapie~ So früh wie möglich und konsequent beginnen!~ Körperliche Aktivität und Wirbelsäulen-Gymnastik~ Stopp den Knochenräubern (Rauchen!)~ Die Sturzgefahr reduzieren!~ Insgesamt 1000 mg Kalzium/d und 1000 JEVitamin D/d
("lOooer-Regel")
Schmerztherapie~ Physikalische Therapie~ Peripher wirkende Analgetika~ Nichtsteroidale Antiphlogistika (Cox-z-Hernmer)~ Opioide kurzzeitig bei Frakturschmerz~ Aminobisphosphonate i.v, monatlich
Hormontherapie~ Östrogen/Gestagen (HRT) postmenopausal und nur bei Wechsel-
beschwerden! Kontraindikationen ausschließen und Aufklärungs-gespräch über Risiken! Viele Patientinnen brechen die HRT inner-halb von 3 Jahren ab!
~ Testosteron (i.m., Pflaster, Gel) bei Männern mit Mangel (vorherPSA bestimmen!)
244 Osteoporose kompakt---- - ----
Bisphosphonattherapie~ Alendronat 70 mg oder Risedronat 35mg als "Wochentablette".~ Alendronat 10 mg oder Risedronat 5 mg als "Tagestablette".~ Orale Bisphosphonate genau nach Vorschrift einnehmen.~ Bisphosphonate stets mit Vitamin D und Kalziumgabe!~ Kontraindikationen sind Schwangerschaft und Stillzeit.~ Bisphosphonate auch bei Männern mit Osteoporose.~ Bei oralen Einnahmeproblemen Aminobisphosphonat i.v, alle
3 Monate (noch keine Zulassung bei Osteoporose).
Raloxifentherapie~ Raloxifen 60 mg/d oral, bei postmenopausalen Frauen .~ Keine Einnahmeprobleme, gut verträglich, Patientin muss nicht
nüchtern sein!~ Raloxifen stets mit Vitamin D und Kalziumgabe!~ Zusatznutzen an Brust und kardiovaskulärem System.
Parathormontherapie~ Bei manifester Osteoporose postmenopausaler Frauen osteoana-
bole Therapie mit Teriparatid 20 Ilgsubkutan täglich möglich.
Andere Therapien~ Etidronat, Fluoride oder Kalzitonin sind nicht mehr zu empfehlen.~ Aktives Vitamin D nur bei Nieren- oder Leberkrankheiten.
Behandlungsstrategie~ Stufe 1: Basistherapie - der Patient ist gefordert: mit Bewegung,
Ernährung, Lebensstil, Kalzium und Vitamin D. DXA-Kontrollejährlich. Falls weiterer Abfall der Knochendichte:
~ Stufe 2: Medikamentöse Therapie - der Arzt ist gefordert: Raloxi-fen, Alendronat oder Risedronat: falls die Basistherapie nicht aus-reicht oder bereits eine Osteoporose vorliegt, konsequenter Einsatzeines der 3 A-klassifizierten Medikamente ("evidence based medi-eine"). DXA-Kontrolle jährlich. Therapiedauer 1-4 Jahre, je nachSchweregrad. Teriparatid als Alternative bei manifester Osteopo-rose zum Wiederaufbau der Knochenstruktur, auch anschließendan Raloxifentherapie. Therapiedauer bis zu 18 Monaten. Konse-quente medikamentöse Therapie vor allem nach operativer/kon-servativer Versorgung von Osteoporose-assoziierten Frakturen zurVerhütung von Folgefrakturen!
Sachverzeichnis
A
Abriebpartikel 194Afroamerikaner 41AIDS 169Aktivität, körperliche 42Akute-Phase-Reaktion 131Alendronat 132,133,186,198Alfakalzidol 117Aigodystrophie (Sudeck-Erkrankung)
32,188-191,216- Stadien 189,190Alkoholkonsum, exzessiver 45,46,90Alter 41,42Aluminium 170Alveole,alveoläre r Knochenschwund
54Amenorrhoe 44Analgetika 107Anamnese 51Anastrozol 183Anbauphase, frühe/späte 17Androgene 13, 18, 20Andropause 149Anorexia nervosa 44, 46Antazida, aluminiumhaltige 94Antiandrogene 184Antibiotika 94Antidepressiva 94Antikoagulanzien 94,166Antikonvulsiva 94Aortenanomalie 162Aortenkalk 64Apoptose 129,130 ,148,174Armspannweite 52Aromatase 18Aromatasehemmer 94,143,181,182
ARSBL ("acute, rapid andsevere bone 1055") 36
Arteriosklerose 39, 148Asthma bronchiale 172Astronaut 43ATAC-Studie 183Atrophie, Knochen 15>37Aufstehtest 47Augenentzündung 131Azathioprin 179
B
Baastrup-Zeichen 52Ballonierung 54Bandscheibenvorfall 51Barbiturate 94Bechterew-Erkrankung 51Beckengürtelfraktur 216Belastung, mechanische 21Belegzelle, endostale
("endosteallining cells") 15Bettruhe 42Bewegung 88, 89"biomechanical properties,
extrinsic/intrinsic" 30Biopsie 55,171,193- Beckenkamm 37,80- Indikation 80- Studie 24>33Bisphosphonate 125-137,159 ,160,190,
191- Applikation , intravenöse 135,136- Halbwertszeit 131- intravenöse Gabe, Onkologie 186- Kontra indikationen 131,132
246 Sachverzeichnis---------
- molekulare Struktur 127- Monitoring 136,137- Pharmakokinetik 126-131- Resorption 131- Resorptionsmarker 137- Substanzen 132-135- Therapiedauer 136- Therapieversager 136,137- Toxizität 131,132- Überblick 126- Wirkmechanismus 126-131Bisphosphonate, immunhistologischer
Nachweis 38Blutdruck 39,88BMD ("bone mineral density") 8,97BMI ("body-mass-index") 201BMP ("bone morphogenie protein")
7,13brauner Tumor 56Brustkrebs 141- Hypogonadismus 181-183- Risiko 143BSP("bone sialoprote in") 78Budesonid 177
c
Canaliculi 14Carbamazepin 94,172Cathepsin K 18Cholesterinspiegel 39,59Clodronat 135,183CML (chronische myeloische
Leukämie) 168Cola 90Colitis ulcerosa 167Colles-Fraktur 215Computertomographie (CT) 58- periphere quantitative (pQCT) 65,
66- quantitative (QCT) 65,66"Consensus Conference
on Osteoporosis" 25Coumestane 121COX-2-Hemmer 107,108Crohn-Erkrankung 167"cross-linking" 7, 29, 77
CTX 140Cushing-Erkrankung 166Cyclosporin A 179
D
Darmerkrankung, entzündliche 95Darmoperation 95,167Deckplatteneinbrüche 86Depression 44,45Dexamethason 93DHEA (Dehydroepiandrosteron)
123, 124DHS (dynamische Hüftschraube)
207,208Diabetes mellitus 95,167Diagnostik 49-80- Computertomographie (CT)
58,65,66- Knochenbiopsie (5. Biopsie)- Knochendichtemessung
(5. auchdort) 58-73- Labordiagnostik 73-80- Leitsymptome 49-54- Magnetresonanztomographie
(MRT) 58- Mikroradioskopie 57- Morphometrie 56,57- Röntgen, konventionelles 54-56- Skelettszintigraphie 57,58- Übersicht, Tabelle 50Dichte- Knochendiehte 27- Knochenmineraldichte (BMD)
8,97Diclofenac 106Dosisfindungsstudie 98Doxorubicin 185DVO(Dachverband Osteoporose) 64DXA-Methode ("dual energy X-ray
absorptiometry") 61-65- .full body DXA scanner" 62- Strahlenbelastung 64- Vorteile 65DXL (Dualröntgen und
Lasertechnologie) 68
E
Eiweiß 92Empfehlungsgrade 99"empty box" 54Endok rinologie 166, 167Endost 28"endosteallining cells"
(endostale Belegzelle) 15Entwicklungsländer 113Erbfaktoren 40,41Erbkrankheiten 167, 168Ermüdungsbruch 30, 44Ernährung, knochenfreundliche
82Ernährungsplan 111Essstörung 44Etidronat 134"evidence based rnedicine" 98-103,
158- "levels of evidence" 98Exemestan 183
F
Fallneigung 47,202"fast loosers" 174Fehlernährung 46Femur, proximales, Fraktur 206-209- Formen, Abbildung 207,208- Versorgung , Abbildung 207Femurnagel 209Ferse 68Fett 92Fibrinogen 142Fibromyalgie 51Fibulafraktur 216Finger 69FIT-Studie
("fracture intervention trial") 133FK506 179"Flash -Beam"-Technologie 64Fluoride 146,147- "slow-release" 147Fluorose 56- iatrogene 146Folsäure 86
Sachverzeichnis 247
Fraktur- Beckengürtel 216- Colles-Fraktur 215- Definition 30,31- Ermüdungsbruch 30, 44- Femur, proximales 206- 209- Fibula 216- Folgefrakturen, Prävention 204,
2°5- .fragility fractures" 12,30,200- Fußwurzelknochen 216- gesellschaftspolitische Bedeutung
199- Heilung 86- Humerusfraktur, subkapitale 216- Infraktion 31- Keilfraktur 212- Kompressio nsfraktur 31,212- Lokalisation 206-216- - Abbildung 200- .Jow trauma fracture" 30- "microcracks" 12- Mikrofraktur 12, 14, 29, 107, 210- Nachsorge, Richtlinien 205,206,
218- - Begleitformular für den Arztbrief,
Abbildung 217- Oberarm 216- Oberschenkelhals 3,45,199,205- pathologische 30- Problemfraktur 208- Radiusfraktur, distale 215- Rippen 216- Risikofaktoren 2, 59,200-2°3,208- Tibia, distale 216- Unterarm 215,216- vorausgegangene 42- Wirbelkörper 209-215Frakturregister 205Frakturschmerz, Therapie- akute Phase 1°7,108- chronische Phase 108,109Fruchtsäfte 84
248 Sachverzeichnis---- - ----G
Gammanagel 209"gap junction" 14Gastroenterologie 167gastrointestinale Beschwerden 131Gehtest 47Gelenkersatz, endoprothetischer
193-198Gemüse 82Gene 21,22- genetische Syndrome, Tabelle 40Genistein 123Geschlecht 41, 42Getreideprodukte 82Gewichtheber 89Glasschneidermodell 139Glukokortikoide 93GnRH ("Gonadotropin-Releasing-
Hormon") Analoge 181,184Gonarthrose 53Gorham-Stout-Syndrom 32,192,193Größenabnahme 52Gruen, Zonen der Prothesenlockerung
196
H
HAART 169Hämatologie 168,169hämolytische Syndrome, congenitale
169Haut 54Hautallergie 131Hemialloarthroplastik,
Oberschenkelhals 207- bipolare 209Hemiplegie 43HERS-Studie 120Herzinfarkt 51Herzinsuffizienz 166- chronische 95Herzklappe- Anomalie 162- Operation 166Herztransplantation 166Hilfsmittel, orthopädische 213
"hip axiallength" 57Histologie, histologische Paramenter
37Hitzewallung 142HIV-Infektion 169Hochleistungssportler 43Hodgkin-Erkrankung 184Hormone 14- Risikofaktoren 46,47- systemische 18-20Hormonersatztherapie (HRT) 117-125- Frauen 117-119- Risiken/Nebenwirkungen 119,120Hüfte 68Hüftkopferhaltende Verfahren,
Oberschenkelhalsfraktur 208Hüftprotektor 47Hüftschraube, dynamische (DHS)
207,208Humerusfraktur, subkapitale 216Hydroxylapatit 65,146- Kristalle 126Hydroxylprolin 78Hyperkalzämie 116,125Hyperkalzurie 31,117,162Hyperkortisolismus 166Hyperparathyreoidismus (HPT) 55,
56- primärer (pHPT) 166- sekundärer 201Hyperphosphaturie 31Hyperthyreoidismus 166Hypogonadismus 46,124,150,166- Brustkrebs 181-183- maligne Lymphome 184- Prostatakrebs 184Hypokalzämie 132Hypothalamus 22
Ibandronat 134,135,183,186,191-193,198
ICS ("inhalation corticosteroidtherapy") 177
Ifosfamid 185Immobilisation 43
Implantat-Mikrobewegung 195Inaktivitätsosteoporose
(Immobilisationsosteoporose)32,157,194
Infektionskrankheiten 169Infraktion 31Insulin 18"insulin-like growth factor" 144Involutionsosteoporose 33-35Iprifiavon 122ISCD ("International Society
of Clinical Densiometry") 62Isofiavone 121, 122Isoniazide 94
J
jamshidi-Nadel 80
K
Kaffee 90Kallusbildung, hyperplastische 162Kalzifizierung, ektop ische 116Kalzitonin 18,107,145,146,159Kalzitriol 117,158Kalzium 110-113- Aufnahme 112- Ausscheidung 78- gebundenes 112- kalziumreiche Kost 81-8 5- natürliches III- Präparate III- Quellen 83- Stoffwechsel 110- Tabletten 84- tägliche Mengen, Empfehlung,
Tabelle 82- Zufuhr, ungenügende 44Kalziumkarbonat IIIKalziumoxalatsteine 116Kardiologie 166Käse 82Kaukasier 41Keilfraktur, Wirbelkörper 212Keratokonus 162
Sachverzeichnis 249---------
Kindheit 81"kiss ing spine" 52Knochen- Biologie 5-24- kortikaler 10- spongiöser 10Knochenabbau, Parameter 77Knochenatrophie 15,37Knochenbewusstsein 3Knochendichte 27Knochendichtemessung 58-73- Auswahl der Knochen 67-69- Geräte 60-67- Indikation 58,59,69-72- Kinder 72, 73- Strahlenexposition 73Knochene rkrankung, adynamische
171Knochenmarködem 191Knochenmasse 8, 26, 69- maximale ("peak bone mass")
22-24Knochenmatrix 5,14Knochenmetastasen 51,125,172Knochenmineraldichte (BMD)
8,60,97Knochenneubildung, Parameter 76Knochenräuber 82,90-93Knochenschwund, periprothetischer
(5.auchProthesenlockerung)193-198
Knochenstoffwechsel, Parameterim Blut 170
Knochenszintigramm 106Knochenumbau- Einheiten
("bone remodeling units") 15-18- Marker 75-80- quantitative Parameter, Tabelle 11- Rate 10- Zyklus 15Knochenwachstum ("modeling")
10
Knochenzellen 12-15Knochenzement 214Knoten 9- Dichte, Reduzierung 29Koffein 90
250 Sachverzeichnis---- - ----
Kollagen 6- Typ I 13,162Kompakta 9Kompressionsfraktur 31,212Kontrazeptiva, orale 46Körpergewicht- ideales 93- niedriges 44Körperhaltung 52,87Korsett 213Kortikosteroide 42- ICS ("inhalation corticosteroid
therapy") 177- induzierte Osteoporose 174-178Kortison 18Kortisonempfindlichkeit 174Kosten 3Kreuzschmerz 49Kyphoplastik 108,213- Abbildung 214Kyphose 51
L
Laboruntersuchung 73-80- Knochenumbaumarker 75-80- "screening" 73- Übersicht, Tabelle 74Lactone 121Laktose 82Laktoseintoleranz 167Lebensqualität 98Leberzirrhose 90,117- primäre biliäre 167LEPS("lower extremity pain
syndrome") 146Leptin 22,147Letrozol 183Leukämie, chronische myeloische
(CML) 168Lignane 121, 122Lipidstoffwechsel 138Lithium 94Looser-Umbauzone 31"low trauma fracture" 30LRP5 22LSC("least significant change") 78
Lungenerkrankung, chronische 95Lungenfibrose , zystische 172Lungentransplantation 172Lymphom, malignes 184
M
Magenoperation 95,167Magnesium 84,85,117Magnetfeldtherapie 109Magnetresonanztomographie (MRT)
58Malabsorptionssyndrome 167Mammakarzinom, metastasiertes
55Marcumars' 143Marknagel 216Mastozytose 169Matrix, Knochen 5,14mechanosensorische Zelle 14Medikamente, Risikofaktoren 47,93,
94Menopause 82,117- männliche 152Metaanalyse 98Metakarpale 57Metalloproteinase 7Methotrexat 185"microcracks" 12Migration 195Mikroarchitektur 30Mikrofraktur 12, 14, 29, 107Mikroradioskopie 57Milch/Milchprodukte 82Mineralien 21Mineralisation 7,8, 21,30, 113Mineralstoffe 46, 84Mineralwasser 84Mitralklappenprolaps 162Mobilisierung 108"modeling" (Knochenwachstum) 10Morbus (siehe Syndrome/Morbus)MORE-Studie 140,215Morphometrie 56,57Mortalität- Oberschenkelhalsfraktur 3- Risiko 2
Muskelrelaxantien 42,106Muskeltrain ing 43Muskelzelle 14Myelom, multiples 55, 168
N
Nahrungsmittel, Einfluss aufKalziumstoffwechsel, Tabelle 91
Nandrolondecanoat 125Nasenspray 145Nekrose- avaskuläre 209- vaskuläre 150Nephrologie 169-171Nervenfasern, afferente 130Nervenzellen 22Neurologie 172Niereninsuffizienz 95- chronische 169Nierensteine 162- Bildung 113,116,117Nierentransplantation 170Nikotin 45NOF ("National Osteoporosis
Foundation") 71,218
o
Oberarmfraktur 216Oberschenkelhalsfraktur 3,45 ,199,
205Obst 82OFELY-Studie 200Onkologie 172Opioid 107Orchidektomie 184Orthese 213Osseointegration, Faktoren 194Osteoblasten 13Osteodystrophie, renale 170Osteogenesis imperfecta 162,163- Differentialdiagnose 161- Therapie 162,163- Typen 162Osteokalzin 13, 86
Sachverzeichnis 251---------
Osteoklasten 12,13Osteologie 4Osteomalazie 31,37,51,55,114Osteomyelitis 55Osteonektin 13Osteopathie- AIDS 169- diabetische 167Osteopenie 35- Definition 27Osteophyt 55Osteoporomalazie 37,167,201- medikamenteninduzierte
187,188Osteoporose- Definition 25-28- Einteilung
fokale 31- - generalisierte 31,32
Histologie 37,38idiopathische junger Erwachsener
33- - idiopathische juvenile 32, 33,
159-161- - Inaktivitätsosteoporose
(Immobilisationsosteoporose)32,157,194
- - Involutionsosteoporose 33-35- - manifeste (schwere) 35- - postmenopausale 32,33- - präklinische 35- - regionale 31- - Schweregrad 35-37- - sekundäre 164-166- - systemische 31- - transiente (transitorische)
32,15°,191,192- beim Kind 154-163- - Ätiologie 154- - Definition 155-159- - Therapie 158,159- kortikosteroidinduzierte 174-178- Lokalisation 28, 29- beim Mann 149-154- - Prävention 153
Risikofaktoren 150- - spezifische Merkmale 152- - Therapie 153,154
252 Sachverzeichnis---- - ----
- Risiko- - Erkrankungen, Tabelle 164,165- - Medikamente, Tabelle 173- sekundäre 44- Stadiensystem, klinisches 36- Studien, Probleme der
Interpretation 103,104- Transplantationsosteoporose 179,
180- tumortherapieinduzierte 180,181Osteoporose-Bäuchlein 52Osteoprotegerin (OPG) 21Osteoprotektion 186Osteozyten 13Osterix 21Östrogen, pflanzliches
(Phytoöstrogen) 90,121 -123Östrogenagonist 138Östrogenrezeptor 13,122,138- SERMs(selektive Östrogenrezeptor-
modulatoren) 123,137-143Oxalsäure 116
p
Paget-Erkrankung 55,125,197Pamidronat 135,186Pankreas- Insuffizienz 167- Tumor 51Paralyse 43Paraplegie 43Parathormon 18,92,143-145- "parathormon-related proteins"
172
"patient's value" 98"peak bone mass"
(maximale Knochenmasse) 22-24Perforation, Knochenbälkchen 29"phantom bone" (Gorham-Stout-
Syndrom) 32,192,193Phenytoin 94Phosphate 92Phytomenadion 117Phytoöstrogen 90,121-123"picture frame" 54piezoelektrischer Effekt 109
Polyarthritis, primäre chronische(PcP) 94> 173
Polycythaemia vera (PV) 168Prävention 81-95Prednison 93PREVOS Studie 148Problemfraktur 208Propranolol 22Prostaglandine 20- Prostagiandin E 176Prostata- Hypertrophie 124- Karzinom 124, 184Prothesendesign 195Prothesenlockerung- aseptische 194- Behandlungsstrategie 196- Diagnostik 195,196- Faktoren 194- septische 195- Therapie 197,198- Zonen,Gruen 196Protonen-ATPase 102,130PSA (prostataspezifische Antigen) 124Pseudarthrosenbildung 209Pulmologie 172
Q
QUI ("quantitative ultrasound index")66,67
R
Rachitis 3,114"radiolucent lines" 195Radius 69Radiusfraktur, distale 215Raloxifen 137-143,151,181 ,186,198- klinische Sicherheit 142, 143- physiologische Effekte auf Knochen
138,139- Studienlage 139-141- Wirkmechanismus 139- Zusatznutzen, Brust und kardio-
vaskuläres System 141
RANK/RANKL-Osteoprotegerin-System 13
Rasse 41Rauchen 45,89,90Regel.roooer-Regel 116,177.remodellng" 11- "bone remodeling units"
(Knochenumbaueinheiten) 15-18Reparaturmechanismus 30Resorptionsphase 16Rezeptor- ß2-adrenerge 22- Östrogen 13,122,138- - SERMs (selektive Östrogen-
rezeptormodulatoren)123,137-143
Rheumatologie 173Rippenfraktur 216Risedronat 133,134,186,198Risikofaktoren 39-47Röntgen, konventionelles 54-56Rückenschmerz 49-53- akuter 52rückenschonendes Verhalten 86"ruffled border" 12"rugger-jersey-spine" 56Ruhephase 16,17
s
Salz 91Sandwich-Wirbel 56Sarkopenie 149Schallgeschwindigkeit 66Schallschwächung 66Scheitel-Sohlen-Abstand 52Schilddrüsenhormone 18,93Schmerz 51- Osteoporoseschmerz 52- Vernichtungsschmerz 52Schmerzambulanz 106Schmerzsyndrom. komplexes regio-
nales (CRPS,Sudeck-Erkrankung)32,188-191,216
- Stadien 189,190Schmerztherapie 105-109- Frakturschmerz 107-109
Sachverzeichnis 253
- Prinzipien 105- Stufenschema (WHO) 106Schutzreflex 47Schwangerschaft 42, 82Schwerelosigkeit 43Schwerkraft 43Schwimmer 89Screeningmethode 67- laborchemisches 73SERMs (selekt ive Östrogenrezeptor-
modulatoren) 123,137-143Serumlipide 142Sexualhormone 18, 20"Singh-Index" 57Skandinavier 41Skelett 5- appendikuläres 9, 10- axiales 9Skelettläsion. paraneoplastische 172Skelettszintigraphie 57,58Skleren- blaue 162- Ruptur 162Skoliose 51SMP ("sympathetically maintained
pain") 189"society's value" 98Softdrinks 91Sojaprodukte 123Sonnenbad 85Sonnenexposition 114Spickdrahtosteosynthese 216"spine deformity index" 57Spondylarthrose 54Spondylitis 55Spondylophyt 64Spongiosa 9Sport, übermäßiger 43,44Sportarten 88Spurenelemente 117Stabilität, Knochen 201Statine 147,148Steroide- anabole 125- Kortikosteroide 42,174-178Stilbene 121Stillzeit 42, 82Stolpersteine 47
254 Sachverzeichnis---- - ----STRATOS Studie 148"stress-shielding" 195Strontium 144,148Studien, randomisierte kontrollierte
(ReT) 98,100,101Sturzneigung 47,202SXA("single energy X-ray
absorptiometry") 65"sympathetic reflex dystrophy"
(Sudeck-Erkrankung) 32,188-191,216
- Stadien 189,190Syndrome/Morbus- Bechterew-Erkrankung 51- Crohn-Erkrankung 167- Cushing-Erkrankung 166- Gorham-Stout-Syndrom 32,192,
193- Hodgkin-Erkrankung 184- Klinefelter-Syndrom 124- Paget-Erkrankung 55,125,197- Sudeck-Erkrankung 32,188-191,
216
T
Tacrolimus 179Tamoxifen 137,138,181Tannenbaumphänomen 52Taubheit 162Teenager 81Telopeptide 77Tennis 88Teriparatid 144,145,154Testosteron 46, 89, 124- Ersatztherapie 149,153- Mangel 151,153Tetrazykiine 148Teufelskreis 1Therapie 97-148- antiresorptive Substanzen 97- Behandlungskonzept 104, 105- Behandlungsstrategie 104,105- Bisphosphonate (5.auchdort)
125-137, 159, 160, 186, 190, 191- Dosisfindungsstudie 98- "evidence based medicine " 98-103
- Fluoride 146,147- Hormonersatztherapie 117-125- Kalzitonin 145,146- Kalzium (5.auchdort) 110-113- Magnetfeldtherapie 109- osteoanabole Substanzen 97, 98- Parathormon (5.auchdort)
143- 145- Raloxifen (5.auchdort) 137-143,
151,181,186,198- Schmerztherapie (5.auchdort)
105-109- Vitamin D 113-117Thrombospondin-z 7Tibia, distale , Fraktur 216Tibolon 119Totalendoprothese 209Tragende Säule 54Trajektionslinien 9Tramadol 106transkriptionale Regulation 21,22Transplantationsosteoporose 179,180"T-score" 27"turnover, highllow" 15,75,174
u
Übersäuerung 92, 93Ultraschallmessung, quantitative
66Umschaltphase 17Unterarmfraktur 215,216Untersuchung, körperliche 51
v
"vanishing bone disease"(Gorham-Stout-Syndrom)32,192 ,193
VDS ("vertebral deformation score")56
Vererbung 40, 41Vertebroplastik 108,213- Abbildung 214Vertikalisierung 54V-H+-ATPase 18
Vitamine 21- fettlösliche 116- Vitamin A 86,117- Vitamin B12 86- Vitamin C 85- Vitamin D 85,113-117- - aktives 116,117- - empfohlene Tagesmenge 113- - Intoxikation 116- - Stoffwechselwege 114- - - Beeinflussung 187,188- - Synthese , Haut 114- - im Wachstum 115- Vitamin K 86,117Volkskrankheit 1, 2Vorsorgeprogramm 81Vorsorgeuntersuchung 39VTE (venöse thrombembolische
Ereignisse) 142
w
Wachstumsfaktoren 147Wachstumshormone 18,158Wadenkrampf 143"watch and wait"-Strategie 159WHI ("Women's Health Initiative
Study") 119,120WH0 (Weltgesundheitsorganisation)- Definition Osteoporose 25- Schmerztherapie, Stufenschema
106
Wirbelkörperfraktur 209-215- bikonkave 210- Formen und Schweregrade,
Abbildung 210- Häufigkeit,Abbildung 211- Keilfraktur 212- Kompressionsfraktur 212- Symptome 212Wirbels äule 67Wirbelsäulengymnastik 109Witwenbuckel 53Wolffsches Gesetz 88,195
Sachverzeichnis 255
z
Zähne 54- Anomalie 162Zementlinien 8Zoledronat 135,183,186,192,193,198"Z-score" 65Zucker 90,91Zwei-Phasen-Komponente 7Zytokine 20,21- postinflammatorische 194Zytostatika 94
/ColorImageDict > /JPEG2000ColorACSImageDict > /JPEG2000ColorImageDict > /AntiAliasGrayImages false /CropGrayImages true /GrayImageMinResolution 149 /GrayImageMinResolutionPolicy /Warning /DownsampleGrayImages true /GrayImageDownsampleType /Bicubic /GrayImageResolution 150 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50000 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict > /GrayImageDict > /JPEG2000GrayACSImageDict > /JPEG2000GrayImageDict > /AntiAliasMonoImages false /CropMonoImages true /MonoImageMinResolution 599 /MonoImageMinResolutionPolicy /Warning /DownsampleMonoImages true /MonoImageDownsampleType /Bicubic /MonoImageResolution 600 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50000 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict > /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox true /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (None) /PDFXOutputConditionIdentifier () /PDFXOutputCondition () /PDFXRegistryName () /PDFXTrapped /False
/CreateJDFFile false /Description > /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ > /FormElements false /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles false /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PreserveEditing true /UntaggedCMYKHandling /LeaveUntagged /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ]>> setdistillerparams> setpagedevice